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Abstract
Background: The abnormal epithelial-mesenchymal restorative capacity in idiopathic pulmonary fibrosis (IPF) has
been recently associated with an accelerated aging process as a key point for the altered wound healing. The
advanced glycation end-products (AGEs) are the consequence of non-enzymatic reactions between lipid and protein
with several oxidants in the aging process. The receptor for AGEs (RAGEs) has been implicated in the lung fibrotic
process and the alveolar homeostasis. However, this AGE-RAGE aging pathway has been under-explored in IPF.
Methods: Lung samples from 16 IPF and 9 control patients were obtained through surgical lung biopsy. Differences in
AGEs and RAGE expression between both groups were evaluated by RT-PCR, Western blot and immunohistochemistry.
The effect of AGEs on cell viability of primary lung fibrotic fibroblasts and alveolar epithelial cells was assessed. Cell
transformation of fibrotic fibroblasts cultured into glycated matrices was evaluated in different experimental conditions.
Results: Our study demonstrates an increase of AGEs together with a decrease of RAGEs in IPF lungs, compared with
control samples. Two specific AGEs involved in aging, pentosidine and Nε-Carboxymethyl lysine, were significantly
increased in IPF samples. The immunohistochemistry identified higher staining of AGEs related to extracellular matrix
(ECM) proteins and the apical surface of the alveolar epithelial cells (AECs) surrounding fibroblast foci in fibrotic lungs.
On the other hand, RAGE location was present at the cell membrane of AECs in control lungs, while it was almost
missing in pulmonary fibrotic tissue. In addition, in vitro cultures showed that the effect of AGEs on cell viability was
different for AECs and fibrotic fibroblasts. AGEs decreased cell viability in AECs, even at low concentration, while
fibroblast viability was less affected. Furthermore, fibroblast to myofibroblast transformation could be enhanced by
ECM glycation.
Conclusions: All of these findings suggest a possible role of the increased ratio AGEs-RAGEs in IPF, which could be a
relevant accelerating aging tissue reaction in the abnormal wound healing of the lung fibrotic process.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, and lethal interstitial lung disease of unknown cause
[1]. IPF is characterized by an histologic pattern of usual
interstitial pneumonia (UIP) which shows a heterogeneous
distribution of dense parenchyma collagen deposition and
active fibroblast foci alternating with areas of normal
parenchyma [2]. An aberrant response of alveolar epithe-
lial cells (AECs) to a repetitive damage that contributes to
the loss of alveolar epithelial structures has been proposed
in IPF physiopathology [3]. Thus, an imbalance between
pro-fibrotic and anti-fibrotic factors leads to an uncon-
trolled extracellular matrix (ECM) formation that modifies
the interstitial configuration [4]. This abnormal wound
healing presents several hallmarks of accelerated aging [5].
Interestingly, the advanced glycation end-products
(AGEs), oxidative non-enzymatic products derived
from modified lipids, proteins or nucleic acids, have
been implicated in some diseases related to an accelerated
aging process [6–8], being proposed as markers of oxidative
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stress and aging [9]. Oxidants such as cigarette smoke and
dietary AGEs would promote the glycation process, result-
ing in accelerated formation of endogenous AGEs, inducing
cellular dysfunction and cell death [10]. Among dozens of
AGEs described, pentosidine and Nε-Carboxymethyl lysine
(CML) are the most studied. An accumulation of pentosi-
dine has been reported in aged skin [11] and in some pul-
monary diseases [12, 13], and a high presence of CML has
been associated with cell response to oxidative stress [14].
The involvement of AGEs in promoting ECM protein
modification and cross-linking is also remarkable [15, 16].
In this way, some studies have related a loss of tendon
viscoelasticity when incubated with AGEs [17], and an in-
crement of arterial stiffness driven by AGEs accumulation
has been described in the aortic walls [18]. Moreover, a
previous report from our group demonstrated stiffness
changes in glycated 3D collagen matrices and fibroblast
phenotypic transformation [19]. This type of in vitro
model would mimic the cross-links and AGEs generation.
Finally, AGEs can glycate some plasmatic proteins, such
as globulins or albumin, changing their physicochemical
properties [20, 21].
On the other hand, the effect of AGEs on cellular reac-
tions has been suggested to be closely related to their re-
ceptor, RAGE [22, 23]. However, RAGE is a member of the
immunoglobulin superfamily of receptors [24] that is highly
expressed in type I AECs of healthy lungs [25], and has
been related with the differentiation of type II to type I
pneumocyte cells, lung development, re-epithelialization,
and maintenance of epithelial adhesion to basement mem-
brane [26–28]. RAGE can be located in the cell membrane
(full-length RAGE, FL-RAGE), or soluble in the extracellu-
lar space (soluble RAGE, sRAGE), without the transmem-
brane and cytosolic domains [29]. Remarkably, different
roles of these two isoforms of RAGE binding the AGEs
have been suggested. AGE-bound FL-RAGE activate an in-
flammatory signaling pathway via the nuclear factor kappa
B (NF-κB) that could increase RAGE expression, enhance
pro-inflammatory mediators, modify oxidative balance, acti-
vate apoptosis, and block AGEs degradation [30]. Mean-
while, a preventive effect of their signaling pathway has
been proposed when sRAGE joins AGEs [31]. Although
the involvement of AGEs/RAGEs in the pulmonary fibrotic
process remains unclear, some research groups have sug-
gested a different pattern of expression, mainly for RAGEs
[32–38]. Therefore, our study aims to evaluate the presence
of AGEs in relation with RAGEs in IPF lungs, and the pos-
sible effect of AGEs on cell behavior.
Methods
Ethical statement
Control human lung samples were obtained from the
distal area of 9 lobectomies of cancer, which showed a
preserved pulmonary architecture without emphysema,
infection or inflammation. IPF samples were obtained
from 16 subjects who underwent surgical lung biopsy
for diagnosis. The included IPF cases were discussed in
the multidisciplinary Interstitial Lung Diseases Committee
of the University Hospital of Bellvitge and were reported as
histological UIP pattern in accordance with the American
Thoracic Society/European Respiratory Society criteria [1].
All patients provided written informed consent and the
study was approved by the Ethics Committee of our center
(CEIC, ref. PR202/08).
Patient characteristics
Both populations, controls and IPF, had similar demo-
graphic features without statistical differences: range of
age (57.60 ± 7.47 and 63.61 ± 6.67 years, respectively) and
male–female ratio in both groups (Table 1). Both groups
included a high proportion of ex-smokers, and a few
current smokers and non-smokers, with the duration of
smoking cessation of 13.20 years ± 14.13 for the control
group and 15.14 years ± 11.97 for IPF patients, showing
no differences between both groups (p = 0.77). Further-
more, there were no differences between both groups in
the average of pack-years (p = 0.94). The pulmonary func-
tional test (PFT) showed significant differences between
IPF and controls in forced vital capacity (FVC) and diffus-
ing capacity for carbon monoxide (DLCO) (p < 0.01)
(Table 1). Diabetic patients from controls and IPF were
excluded from the study to avoid the AGEs formation in-
herent to diabetes mellitus disease.
Western blot analysis
Tissue samples were homogenized in radioimmunoprecipi-
tation assay buffer (RIPA buffer) pH 7.60 with protease
inhibitors (Sigma-Aldrich, USA) in Ultra-Turrax T25 basic
(IKA®-Werke, Germany). Protein concentration was deter-
mined by BCA Protein Assay Kit (Thermo Fisher Scientific
Inc., USA) and 30 μg of sample was loaded in Mini-
PROTEAN® TGX™ precast 4–15 % polyacrylamide gel
(Bio-Rad, USA) under reducing conditions. Gels were
Table 1 Group features
Patient characteristics Control IPF p-value
Total 9 16 -
Gender (Male/Female) 7/2 13/3 -
Age 57.60 ± 7.47 63.61 ± 6.67 0.03
Smoking (Current/Former/Never) 2/5/2 4/10/2 -
Pack-years 24.91 ± 25.18 24.18 ± 26.81 0.94
Smoking cessation (years) 13.20 ± 14.13 15.14 ± 11.97 0.77
% FVC 99.36 ± 14.55 77.92 ± 15.05 0.00
% DLCO 89.43 ± 13.98 56.91 ± 18.44 0.00
Data expressed in mean ± SD. FVC forced vital capacity, DLCO diffusing
capacity for carbon monoxide. Statistical differences were valued
at p-value < 0.01
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transferred onto nitrocellulose membrane in semi-dry
Trans-Blot® Turbo™ Transfer System (Bio-Rad). After
blocking with TBS-T 5 % BSA (Sigma-Aldrich), the mem-
branes were incubated with rabbit polyclonal anti-AGEs
1:10000 (ab23722; Abcam, UK), rabbit polyclonal anti-
CML 1:500 (ab27684; Abcam), mouse monoclonal anti-
Pentosidine 1:1000 (KAL-KH012; Cosmo Bio Co., Japan) or
mouse monoclonal anti-RAGE 1:1000 (ab54741; Abcam),
and mouse monoclonal anti β-actin 1:2000 or mouse
monoclonal anti α-tubulin 1:2500 (A1978 and T6199, re-
spectively; Sigma-Aldrich) as a loading control during 1 h
at room temperature (RT). Then the membranes were in-
cubated with a secondary antibody: goat anti-IgG rabbit or
anti-IgG mouse HRP conjugate (P0448 and P0447, respect-
ively; Dako, Denmark) 1:1000 (for anti-AGE or anti-RAGE,
respectively) in TBS-T during 1 h at RT. Membranes were
washed in TBS-T 3 times for 5 min after the primary and
secondary antibody incubation. Immunoblotting was
detected by chemiluminescence in a LAS-3000 Imaging
System (Fujifilm Holdings Corporation, Japan) with Super-
Signal™ West Pico (Thermo Fisher Scientific), following the
manufacturer’s recommendations. Densitometry was mea-
sured by MultiGauge image analyzer software (Fujifilm).
The antibodies used for global AGEs, pentosidine and
CML, recognized any proteins which contain these re-
gions in its structure, so the three bands observed in
Western blot analysis (named AGEs/Pen/CML 1, 2 and 3)
corresponding with three different molecular weights
matched with three groups of AGE-modified proteins.
Reverse transcriptase PCR
Total mRNA was extracted from IPF and control lung
samples using TRIzol® reagent procedure (Invitrogen,
UK) following the manufacturer’s instructions. Samples
were quantified, and Reverse transcription reaction was
done with 1 μg by iScript™ cDNA Synthesis Kit (Bio-
Rad) in a thermal cycler (Bio-Rad). PCR was performed
with DNA polymerase (Biotools B&M Labs, Spain) fol-
lowing the manufacturer’s advice; cDNA was mixed with
RAGE primers (164 bp): sense 5′-CAGGACCAGG
GAACCTACAG-3′ and antisense 5′-CATGTGTTGGG
GGCTATCTT-3′; and β-actin primers (302 bp) were
used as a housekeeping gene: sense 5′-GCACTCTTC
CAGCCTTCCTTCC-3′ and antisense 5′-TGCTTGCT
GATCCACATCTGCT-3′ (Sigma-Aldrich). Amplified sam-
ples ran in 2 % agarose gel electrophoresis with ethidium
bromide. Then the gel was revealed within an UV chamber
and images were developed in instant film to be digitalized
afterwards.
Immunohistochemistry
Control and IPF tissue samples were fixed using a 4 %
formaldehyde solution in phosphate buffered saline
(PBS) and embedded in paraffin. Then the samples were
cut in 4 μm sections for the immunohistochemical pro-
cedures. Slides were deparaffinized and rehydrated, and
then endogenous peroxidases were blocked by incubating
samples with 3 % H2O2 for 10 min. AGE-BSA immuno-
staining was performed with polyclonal rabbit anti-AGEs
antibody (Abcam), following the manufacturer’s instruc-
tions of Vectastain™ Elite Avidin-Biotin Complex Kit (ABC
Kit) (Vector Laboratories, USA). Briefly, antigen retrieval
was performed with boiling Tris-EDTA buffer pH 9. Subse-
quently, slides were blocked in an incubation solution (PBS,
0.2 % Triton X-100 and 0.2 % bovine gelatin) with 20 % of
normal goat serum for 1 h at RT. Then, samples were incu-
bated with primary antibody diluted 1:5000 in the incuba-
tion solution overnight at 4 °C. After that, slides were
incubated in goat anti-rabbit IgG antibody 1:400 from
Vectastain™ Kit during 1 h at RT. Later, slides were
incubated with ABC Kit for 1 h at RT. Slides were
washed with PBS 3 times for 5 min each, between
incubations. A brown color was revealed with 3,3′-Diami-
nobenzidine tetrahydrochloride hydrate (Sigma-Aldrich)
in PBS, and sections were counterstained with Harris’
haematoxylin (Casa Álvarez S.A., Spain) and cover-slipped
with DPX (Merck Millipore, Germany).
RAGE immunostaining was made with mouse monoclo-
nal anti-RAGE antibody (Abcam), following manufacturer’s
instructions. In this case, antigen retrieval was made with
boiling citrate buffer pH 6 (Dako). The antibody was di-
luted 1:200 in the incubation solution with 1 % of normal
goat serum overnight at 4 °C. After that, slides were incu-
bated in goat anti-mouse IgG2a HRP-conjugated antibody
1:200 (NB7516; Novus Biologicals, USA) diluted in the in-
cubation solution with 1 % of normal goat serum. Revealing
and counterstaining were performed following the same
protocol explained above. A negative control was made by
incubating control slides without primary antibody in all
the immunohistochemical assays. The strong brown stain-
ing was considered as a positive signal. Images were evalu-
ated by two expert pathologists blinded to the sample.
Cell viability assay
In order to evaluate the AGEs effect in cell viability, pri-
mary fibroblasts from IPF lungs, A549 cell line (ATCC,
Manassas VA, USA), and human airway epithelial (HAE)
cell line (CRL-4011™, ATCC) were treated with AGE-BSA.
AGE-BSA was prepared following the protocol of Khan
et al. [39]. Briefly, 50 mg/mL BSA (Sigma-Aldrich) was in-
cubated with 1 M D-Ribose (Sigma-Aldrich) in PBS pH 7.4
for 20 days at 37 °C. In addition, BSA was incubated with-
out D-Ribose as a control. After that, the solutions were
dialyzed and filtered through 0.22 μm membranes (Merck
Millipore) to remove D-Ribose debris; and then the pres-
ence of AGEs were checked and quantified by fluorescence
(wavelength emission 440 nm/excitation 370 nm) and BCA
Protein Assay Kit.
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Fibrotic fibroblasts were isolated from IPF patients
that underwent surgical lung biopsy and grew in DMEM
(Gibco™, Thermo Fisher Scientific, USA) with 10 % FBS.
A549 was cultured in F12K medium (Lonza, Switzerland)
with 10 % FBS. HAE cell line was cultured in Bronchial
Epithelial Cell Growth Medium (BEGM, Lonza).
Quick Cell Proliferation Colorimetric Assay Kit (MBL
international, USA) was performed in 96-well plates
following the manufacturers’ recommendations. Cells
were seeded at 1 × 104 cells/well and were incubated in
medium with 2 % FBS for 24 h before the experiment.
Then cells were treated with different concentrations of
AGE-BSA for 3 h. A well without cells was assessed for
all conditions as reference value. Reagent was added to
each well for an additional 2 h and the plate was shaken
and read in the Thermo Scientific Multiskan® EX (Thermo
Fisher Scientific) at 450 nm, and absorbance was adjusted
to the measurement in the reference value for each
condition.
3D cell culture into glycated matrix
Three-dimensional culture based on glycated collagen
matrix was performed to evaluate the behavior of
fibrotic fibroblast cells under the influence of ECM
cross-links and the consequent AGEs production. The
3D collagen matrices were produced using native type
I collagen from bovine dermis at 4 mg/mL (Cosmo
Bio Co., Japan), and were glycated adding ribose at 5
and 15 mM (Sigma-Aldrich), following a previously
standardized protocol [19].
Fibroblasts were added and mixed with the collagen
before polymerization of the gel. Cells were seeded into
96-well plates at 15 × 103 cells/well. After matrix
polymerization, a culture medium with a different concen-
tration of ribose was added. Phenotype changes were eval-
uated by Western blot detection of alpha-smooth muscle
actin (α-SMA) 1/500 (A5228; Sigma-Aldrich) on days 1, 7
and 14, following the procedure described above.
Statistical analysis
Data of experimental groups were compared and analyzed
with IBM SPSS Statistics 23 (IBM, USA). Differences
between the two groups were analyzed by Student’s t-test
or Mann–Whitney U-test when comparing two para-
metric or non-parametric samples, respectively. To evalu-
ate the differences among experimental groups, one-way
ANOVA was assessed. Results are expressed as means ±
SD. The p-value < 0.05 (*) or < 0.01 (**) were considered
statistically significant.
Results
Increased AGEs expression in IPF lungs
Western blot showed an increase of AGEs in IPF lungs,
compared to control samples (Fig. 1, A1). Analyzing the
three bands separately, the significant difference between
both groups was achieved because of the highest expres-
sion of the 25 kDa band of AGEs in IPF samples (p <
0.05, Fig. 1, A2).
The immunohistochemical study of AGEs showed a
different location pattern between both lung sections. In
control pulmonary parenchyma, AGEs had a discontinu-
ous pattern of staining, mainly in the endothelium of ca-
pillaries and veins, and there was a spotted staining in
macrophages cytoplasm (Fig. 1, B1). Furthermore, pneu-
mocytes (Fig. 1, B2) and bronchial epithelium (Fig. 1, B3)
showed a weak staining for AGEs. Interestingly, IPF lung
sections presented the strongest staining around the ECM
proteins (Fig. 1, B4) and the apical surface of reactive
AECs (Fig. 1, B5) and bronchial epithelium (Fig. 1, B6),
while no signal was seen into the fibroblast foci.
Furthermore, two specific AGEs were individually evalu-
ated; pentosidine and CML. Immunoblot analysis showed
a high presence of pentosidine in IPF samples compared
with controls (Fig. 2, A1). The two patterns of bands; 45
and 30 kDa, were significantly increased in IPF compared
to control (p < 0.01, Fig. 2, A2). Meanwhile, Western blot
assessment for CML-modified protein showed three pat-
terns of bands: 109, 69 and 58 kDa (Fig. 2, B1). The high-
est band (109 kDa) and the lowest (58 kDa) were
increased in IPF samples compared with control samples
(p < 0.01, Fig. 2, B2).
Decreased RAGE expression in IPF lungs
Lung homogenates were prepared to evaluate RAGE pro-
tein expression. Western blot analysis showed a strong
RAGE expression in the control group; with two bands at
56 and 46 kDa, which correspond to the membrane or
full-length RAGE (FL-RAGE) and the soluble RAGE
(sRAGE) isoform, respectively (Fig. 3a), as described in
the literature [40]. However, samples from IPF patients
showed almost undetectable protein expression. Densi-
tometry analysis showed a statistically significant decrease
of RAGE protein expression in IPF compared to control
lungs (p < 0.01, Fig. 3b). Analyzing both isoforms separ-
ately, we noticed that sRAGE isoform was 1.67 and 4.17-
folds increased in relation to the FL-RAGE isoform, for
both controls and IPF samples, respectively (Fig. 3c).
Analyzing the gene expression of RAGE, a clear down-
regulation was also observed in IPF lungs, compared
with control lung homogenates (Fig. 3d).
To study the RAGE protein location in cells of human
lung samples, an immunohistochemistry assessment was
performed. Control lungs showed a strong positive stain-
ing for RAGE, mainly located in the cell membrane of
AECs (Fig. 4, A1). Although the pattern of expression
was not continuous around the epithelial membrane sur-
face, we could distinguish the two sides of the alveolar
septa (Fig. 4, A2). In addition, we also observed a weak
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immunostaining inside the cytoplasm of bronchial epi-
thelial ciliated cells (Fig. 4, A3). Additionally, macro-
phages also exhibited a dotted brown staining. In
contrast, the staining was absent in fibroblasts, and was
not clearly defined in the endothelium and the smooth
muscle of blood vessels (Fig. 4, A4). On the other hand,
lung sample sections from IPF patients showed a hetero-
geneous immunostaining pattern. Areas with matrix
deposition and restructured parenchyma did not show
immunostaining (Fig. 4, B1), whereas preserved alveolar
structures presented weak positive signal on the apical
cell membrane surface of AECs (Fig. 4, B2). Meanwhile,
the immunostaining for the RAGE antibody was totally
absent in the hyperplasic AECs and fibroblast foci (Fig. 4,
B3). Likewise, we did not find brown staining either
smooth muscle cells or epithelial cells from vessels and
bronchi (Fig. 4, B4).
Finally, we evaluated the AGEs/RAGEs ratio assuming
a 1:1 equivalent relation between both semi-quantitative
analyses. This ratio was 8.18-folds greater in IPF lungs
compared to control samples, which demonstrate a sig-
nificant imbalance of the AGEs/RAGEs since both in-
crease of AGEs and decrease of RAGEs in IPF lungs
(Fig. 5).
Effect of AGEs in cell viability and phenotype
Cell viability assay showed a different dose–response
curve to AGE-BSA for the cell types. A549 AECs
showed a defined slope (Fig. 6, red line) and the cell via-
bility decreased at all concentrations, with a higher effect
at the maximum concentration tested (150 μM) that as-
sociated less than 30 % viability. Meanwhile, HAE cells
(Fig. 6, green line) had also shown a dose-dependent de-
crease of cell viability with AGE-BSA. By contrast,
Fig. 1 Presence of AGEs in human lung tissue from IPF patients (IPF) and control group (Control). a1 The antibody used for global AGEs
assessment recognized any proteins which contain a glycated region in structure; so the three bands seen (at 60, 50 and 25 kDa) in Western blot
analysis correspond with 3 types of AGE-modified proteins. a2 Although Anti-AGEs immunoblot did not show apparent differences between both
groups, densitometry analysis showed statistical differences only in the band of 25 kDa and when the values of the three AGEs obtained were
considered together. Presence of AGEs was represented as percentage in relation to loading control β-actin (β-act). Statistical analysis was
performed using Student’s t-test (*p < 0.05). b1 Parenchyma of lung control showed positive signal (brown color), mainly associated to lumen and
endothelium of blood vessels and capillaries. b2 Pneumocytes (arrow) showed a weak and discontinuous staining for anti-AGEs antibody.
b3 Ciliated epithelial cells of bronchus showed a blurred pattern of staining in their cytoplasm. b4 Brown immunostaining associated to proteins
from the ECM in IPF lungs. b5 Reactive AECs (arrow) and ECM proteins showed immunoreactivity; contrary to fibroblast foci (star), where
immunostaining was absent. b6 Apical membrane of ciliated cells from bronchus and endothelium of blood vessels also showed staining.
Micrographs recorded at 200X (b1, 4, 5 and 6) and 400X (b2 and 3) magnification
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Fig. 2 Pentosidine and CML expression by Western blot. a1 Anti-pentosidine antibody used for Western blot assessment showed a dissimilar
pattern of bands at 45 and 30 kDa. Two different pentosidine-modified proteins were recognized. a2 Densitometry analyses showed a major
presence of pentosidine in the IPF group compared with the control, for both bands. b1 Anti-CML antibody showed several patterns of bands of
CML-modified proteins: a high band in 109 kDa, and two bands in 69 and 58 kDa. CML at 109 and 58 kDa are stronger in IPF than control lungs.
b2 Densitometry analyses showed a major presence of CML-contained proteins in the IPF group in comparison to the control. Data were represented
as percentage in relation to loading control α-tubulin (α-tub) and β-actin (β-act), respectively. Statistical analysis was performed using Mann–Whitney
U-test and Student’s t-test, respectively (**p < 0.01)
Fig. 3 RAGE proteins and gene expression were decreased in IPF samples. a Immunoblot assay showed two strong RAGE bands in the control
group: 56 (FL-RAGE) and 46 (sRAGE) kDa, respectively, whereas IPF samples showed a weak or absent signal for anti-RAGE antibody. b Densitometry
analysis showed a higher amount of RAGE in the control group in respect to IPF. The total RAGE expression was represented in percentage in relation to
β-actin (β-act) as loading control. c sRAGE/FL-RAGE ratio, for both groups. The sRAGE and FL-RAGE isoforms were both higher in the control group than in
IPF and, interestingly, sRAGE was 1.67 and 4.17-fold higher than FL-RAGE, respectively. d RAGE (164 bp) and β-actin (302 bp) transcripts were amplified by
RT-PCR. Control samples showed more RAGE gene expression than IPF samples. Statistical analysis was performed using Student’s t-test (**p< 0.01)
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human lung fibrotic fibroblasts showed a line tendency
with a smooth slope (Fig. 6, blue line), reaching 60 % of
living cells at the highest AGE-BSA dose.
In addition, fibrotic fibroblasts were cultured into
non-enzymatic glycated collagen matrix to evaluate
their phenotype changes growing in an enriched AGEs
ECM microenvironment. Protein expression of α-SMA
showed a significant increment in all conditions from
day 7 (Fig. 7a). Interestingly, Western blot analysis did
not show significant differences between glycosylated
conditions (with and without ribose) (Fig. 7b).
Discussion
In the last few years, IPF has been proposed as a result
of an accelerated aging process of the lung [5]. Some
findings support ECM as a target of oxidative stress in
the lung and the subsequently produced AGEs, which
are biomarkers of an in vivo aging process that may pro-
mote fibrogenesis [9, 41]. In this line, our results demon-
strate that AGEs are increased in IPF samples at the
same time that RAGEs are decreased. Specifically, two
well-known AGEs, CML and pentosidine-modified pro-
teins, which have been related to aging, tissue stiffness
and AECs apoptosis [11, 14, 18] are significantly overex-
pressed in IPF samples. Some pathogenic features of IPF
may be implicated in the AGEs formation; collagen depos-
ition, aging, oxidative compounds derived from smoking,
dust or diet, and decreases of soluble RAGE are processes
that could enhance the accumulation of AGEs in lung
fibrosis [15].
At the same time, the higher amount of AGEs formation
could influence the perpetuation of the fibrogenic process.
In vitro studies have shown that AGEs could induce cell
toxicity and death [39], delaying wound healing in epithe-
lial cells [42]; whereas enhancing collagen and transform-
ing growth factor (TGF)-β1 synthesis [43]. Additionally,
Fig. 4 Immunostaining of RAGE in control (A) and IPF (B) lung sections. a1 Parenchyma show a strong brown staining, focused in the alveolar
epithelium. a2 Pneumocytes show brown staining over its cell membrane (arrow), although there is a discontinuous pattern. a3 Ciliated epithelial
cells of bronchus show a weak staining pattern. a4 Endothelium and smooth muscle of veins do not show brown staining. b1 Areas of matrix
deposition do not show immunoreactivity. b2 Preserved parenchyma show a weak staining (arrow). b3 Fibroblast foci (star) and AECs (arrow) that
surround these fibroblast foci show almost undetectable immunostaining. b4 No signal was considered in blood vessels and preserved bronchus.
Micrographs were recorded at 100X (b1 and 4), 200X (a1, b2 and 3) and 400X magnification (a2, 3 and 4)
Fig. 5 Ratio of the total AGEs/RAGEs. The proportion between total
AGEs and RAGEs for each sample (IPF and controls) estimated after
the semi-quantitative analysis (densitometry) from WB of AGEs and
RAGE. Bars show the mean ± SD in both groups. The graph shows a
considerable RAGE decrease in IPF samples, around 8.18-fold respect
the control samples. Densitometry is measured by independent pair
observers by using “MultiGauge image analyzer software Statistical
analysis was performed using Student’s t-test (**p < 0.01)
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AGEs induce epithelial-mesenchymal transition (EMT) in
epithelial cells from rat kidney [44], although no EMT ef-
fect has been found in type II AECs from the rat lung
[45]. Actually, some studies have even suggested that
blocking the AGEs might attenuate pulmonary fibrosis
[46]. However, there is scarce information about the effect
of AGEs in human AECs and fibroblasts from lung paren-
chyma. In the present study, we demonstrated, as an ini-
tial approach, that alveolar type II epithelial cell line
viability (A549) and HAE cell line were more sensitive to
the presence of AGEs, while fibrotic fibroblasts had a low
response to high dosage of AGEs; suggesting a different
effect of AGEs, depending on cell type. Although the
A549 cell lines may be suitable for initial exploratory IPF
studies, data derived from such cells must acknowledge
the limitations associated with these tools [47].
In addition, immunohistochemical results showed in-
creased AGEs associated with the hyperplasic AECs, which
suggest that AGEs could induce pro-fibrotic effects such as
loss of epithelium. On the other hand, our results indicate
the presence of myofibroblast transformation from fibrotic
fibroblasts, in part because of the presence of AGEs at the
surrounding ECM. Previous work of our group has demon-
strated that 3D collagen matrices generated under glycation
Fig. 6 Cell viability assay of AGE-BSA in fibroblast, A549 cell line and human airway epithelial (HAE) cell line. Line tendency shows the response of
fibroblast (blue line), A549 cell line (red line) and HAE cell line (green line) to AGE-BSA (0 to 150 μM) after 3 h of incubation. Data is expressed as
mean ± SD. MTT was assessed in triplicate
Fig. 7 Protein expression of α-SMA from fibroblast in glycated matrix. a Fibroblasts were cultured within 3D collagen matrix and collected at days
1, 7 and 14 to study a possible phenotypic profile change. Western blot showed an increment in all ribose concentrations (R0, 5 and 15 mM) by
day. b Densitometry did not find significant differences between control and R5 and 15 mM. The experiment was assessed in triplicate and
represented as percentage in relation to loading control α-tubulin (α-tub). Statistical analysis was performed using Student’s t-test (*p < 0.05)
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present an increase of AGEs, which is time-dependent and
appears 5 days after glycation begins [19]. The AGEs for-
mation is not only dependent on ribose concentration, but
also on the presence of serum and glucose in the media,
which would explain the fact that fibroblast-myofibroblast
transformation appears in glycated 3D matrices, with and
without ribose addition. However, a potential limitation for
the interpretation of this observation is that other non-
controlled collateral collagen cross-link reactions described
at the glycated process of this in vitro model and not asso-
ciated with AGEs formation could also influence in the
myofibroblast transformation.
On the other hand, since a higher presence of RAGE
has been found in healthy pulmonary tissue, in comparison
to other organs, there are many studies that support its
outstanding role in pulmonary homeostasis [25]. Our
results demonstrated that the protein expression of RAGE
(FL-RAGE and sRAGE) was decreased in all fibrotic lungs
compared with control lungs. According to this observa-
tion, Quiesser et al. suggested an important function of
RAGE in cellular adhesion and spreading to the basal
membrane, playing a structural role in the maintenance of
the alveolar epithelium [32]. It has also been demonstrated
that RAGE stimulates elastin expression and plays a sup-
porting role in respiratory mechanics [48]. Furthermore,
RAGE may belong to a family of cell adhesion molecules
[49], making links with basal lamina components such as
type IV collagen or laminin [28, 50]. Thus, hypothetically,
this RAGE down-regulation noticed in IPF lung samples
could reduce the interaction of AECs to ECM and facilitate
the basal membrane disruption, resulting in the occupation
of alveolar spaces. Additionally, our results showed that the
soluble isoform, sRAGE, is the greatest RAGE variant in
the control lungs, with a sRAGE/FL-RAGE ratio of 1.67 in
agreement with other studies performed in human lungs
[51]. Interestingly, it has been described that only 7 % of
RAGE transcript encodes for the main alternative splicing
soluble variant [29], so a greater part of sRAGE might come
from the cleavage of FL-RAGE by metalloproteinases [52],
which are overexpressed in lung tissue and BAL fluids from
IPF patients [53]. Consequently, it could cause the loss of
joins between the type I AECs and the basement mem-
brane, avoiding the normal re-epithelialization in response
to damage [54]. In support of this, our results showed a
sRAGE/FL-RAGE ratio in IPF lungs of 4.17, 2.5 fold in-
creased in respect to the control lungs, in the possible con-
text of the MMPs’ raising in the fibrotic process.
Regarding our immunohistochemical analysis of RAGEs,
a predominance location around the cell membrane of
AECs was observed in control lung tissues, as was previ-
ously described [55]. In contrast, RAGE was totally absent
in the hyperplasic AECs and fibroblast foci from IPF lungs.
Although this decrease of RAGE in fibrotic lung samples
could be explained by the loss of AECs, some studies
suggest that RAGE might be decreased from the beginning
of AECs damage [33, 56]. Likewise, in our study we
have observed that the loss of RAGE was not restricted
only to protein expression, but also to the genetic ex-
pression. Hence, RAGE reduction is not only associated
with Type I AECs’ disappearance as a consequence of
tissue remodeling, but also the areas of preserved par-
enchyma show a decreased RAGE expression.
Although solid evidence demonstrates a complex func-
tion of RAGE in the lung, the implication grade and the
role in lung physiology is still under discussion. Further-
more, the decrease of RAGE expression in IPF, especially
sRAGE, suggests a potential utility to be tested in the fu-
ture as biomarker [57] and therapeutic target [31, 57–59].
Conclusion
In conclusion, our results suggest the implication of
AGEs accumulation beside the decrease of RAGEs in
the altered wound healing of IPF. The current findings
demonstrate that the fibrotic lung presents an AGEs/
RAGEs imbalance, which could associate oxidative damage
in the accelerated aging process. Therefore, the advance in
the knowledge of AGEs-RAGE function in pulmonary
fibrosis, due to the particularities that RAGE presents in
the lung homeostasis and the implication of AGEs in de-
generative diseases and aging, would be essential to explore
through this possible new pathway.
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